



07/03/01

Assistant Commissioner for Patents  
Washington, DC 20231

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
REQUEST FOR FILING APPLICATION UNDER 37 CFR 1.53(b)  
**WITHOUT FILING FEE AND/OR WITHOUT EXECUTED INVENTOR'S DECLARATION**

Atty. Dkt. 620-148

Date: July 3, 2001

1051 U.S. PTO  
09/897412  
07/03/01

Sir:

This is a request for filing a new PATENT APPLICATION under Rule 53(b) entitled:

**USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC FIBROSIS (CF) AND CHRONIC  
OBSTRUCTIVE PULMONARY DISEASE (COPD)**

without a filing fee and/or without an executed inventor's oath/declaration.

This application is made by the below identified inventor(s). Attached hereto are the following papers:

☐ Newly executed Declaration, ☐ Copy of Declaration from prior application, ☒ Abstract

38 pages of specification and claims (including 10 numbered claims), and

9 sheets of accompanying drawing/s.

☐ Record the attached assignment and return to the undersigned.☐ Attached is a Power of Attorney.☒ Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications:**Application Number****Country****Day/Month/Year Filed**

0016441.8

GREAT BRITAIN

4 July 2000

, respectively, the entire content of which is hereby incorporated by reference in this application..

Certified copy(ies) of foreign application(s) is/are attached.

Certified copy(ies) filed on \_\_\_\_\_ in prior appln. no. \_\_\_\_\_ filed \_\_\_\_\_

Petition filed in prior application to extend its life to insure co-pendency.

The prior application is assigned to \_\_\_\_\_

It is hereby requested that the Examiner consider the art cited in the above parent application(s) by applicant and/or  
the Examiner for the reasons stated therein. A listing of that art is attached, but pursuant to Rule 98(d) copies are  
not required.

Applicant claims "small entity" status. ☐ "Small entity" statement attached.Please enter the attached and/or below preliminary amendment **prior** to calculation of filing fee:

Also attached: ☐ Information Disclosure Statement; ☐ Non-Publication Request; ☐ Nucleotide and/or  
Amino Acid Sequence Submission; ☐ Statement deleting Inventor(s) named in prior application; ☐ Other:

Inventor: Richard J. DAVIS Great Britain  
(first) MI (last) (citizenship)  
Residence: (city) Hertfordshire (state/country) United Kingdom  
Mailing Address: Pharmagene Laboratories Ltd, 2 Orchard Road, Royston, Hertfordshire, United Kingdom  
(Zip Code) SG8 5HD

2. Inventor: Keith J. PAGE Great Britain  
(first) MI (last) (citizenship)  
Residence: (city) Hertfordshire (state/country) United Kingdom  
Mailing Address: Pharmagene Laboratories Ltd, 2 Orchard Road, Royston, Hertfordshire, United Kingdom  
(Zip Code) SG8 5HD

☐ See attached sheet(s) for additional inventor(s) information!!

Address all future communications to NIXON & VANDERHYE P.C., 1100 North Glebe Road, 8<sup>th</sup> Floor, Arlington,  
Virginia 22201.

1100 North Glebe Road, 8<sup>th</sup> Floor

Arlington, Virginia 22201-4714

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

BJS:ms

**NIXON & VANDERHYE P.C.**

By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: \_\_\_\_\_